<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775839</url>
  </required_header>
  <id_info>
    <org_study_id>PGX_Clopidogrel_002</org_study_id>
    <nct_id>NCT01775839</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin</brief_title>
  <official_title>Clinical Trial to Evaluate the Influence of Genotype of Drug Metabolizing Enzyme or Transporter and Drug-drug Interactions of Aspirin Co-administration on the PK/PD of Clopidogrel and PK of Digoxin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to evaluate the influence of multiple aspirin administration on PK and PD of
      co-administered drugs
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial to evaluate the influence of genotype of drug metabolizing enzyme or
      transporter and drug-drug interactions of aspirin co-administration on the pharmacokinetics /
      pharmacodynamics of clopidogrel and pharmacokinetics of digoxin in healthy volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC and Cmax of Clopidogrel and Digoxin</measure>
    <time_frame>pre- and post dose of Clopidogrel, Digoxin administration</time_frame>
    <description>(Clopidogrel)Predose and 10, 20, 30, 40, 50 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h postdose on Week 0, 4, 8 (Digoxin) Predose and 10, 20, 30, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 h postdose on Week 0, 4, 8</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>DRUG REACTIONS</condition>
  <arm_group>
    <arm_group_label>Aspirin+Clopidogrel/Digoxin(oral)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin+Clopidogrel/Digoxin(IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin+Clopidogrel/Digoxin(oral)</intervention_name>
    <description>oral administration of digoxin</description>
    <arm_group_label>Aspirin+Clopidogrel/Digoxin(oral)</arm_group_label>
    <other_name>Aspirin</other_name>
    <other_name>Clopidogrel</other_name>
    <other_name>Digoxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin+Clopidogrel/Digoxin(IV)</intervention_name>
    <description>intravenous administration of digoxin</description>
    <arm_group_label>Aspirin+Clopidogrel/Digoxin(IV)</arm_group_label>
    <other_name>Aspirin</other_name>
    <other_name>Clopidogrel</other_name>
    <other_name>Digoxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 20 - 45 years.

          -  A body weight in the range of 50 kg (inclusive) - 90 kg (exclusive) and a body mass
             index (BMI) in the range 18.5 kg/m2 (inclusive) - 27 kg/m2 (inclusive).

          -  Sufficient ability to understand the nature of the study and any hazards of
             participating in it. Provide written informed consent after being fully. informed
             about the study procedures.

        Exclusion Criteria:

          -  Presence or history of hypersensitivity or allergic reactions to drugs including
             investigational product (clopidogrel, digoxin or aspirin)

          -  Clinically relevant abnormal medical history that could interfere with the objectives
             of the study.

          -  A subject with history of gastrointestinal disease or surgery (except simple
             appendectomy or repair of hernia), which can influence the absorption of the study
             drug.

          -  A subject whose lab test results are as follows; Platelet count or PT, aPTT &lt; 0.9 x
             lower limit of reference range of &gt; 1.1 x upper limit of reference range.

          -  A subject whose SBP is over 160 mmHg or below 90 mmHg and DBP is over 100 mmHg or
             below 50 mmHg.

          -  Clinically significant abnormal findings of ECG during screening test.

          -  Presence or history of drug abuse or positive result in urine drug screening test.

          -  Participation in other clinical trial within 2 months before first dose.

          -  Use of CYP inducer (ex. rifampin) within 4 weeks before first dose.

          -  Use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter
             medication or vitamin substances within 1 week before first dose.

          -  Use of grapefruit juice within 1 week before first dose.

          -  Blood donation during 2 months or apheresis during 1 month before the study.

          -  Use of alcohol over 21 units/weeks

          -  Smoking of more than 10 cigarettes/days within 3 months before first dose.

          -  Subject judged not eligible for study participation by investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNUH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trials Center</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2013</study_first_posted>
  <last_update_submitted>June 8, 2014</last_update_submitted>
  <last_update_submitted_qc>June 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

